scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
scPharmaceuticals (SCPH) reported first quarter 2024 financial results, with notable achievements in FUROSCIX®. The company generated $6.1 million in net FUROSCIX revenue, despite a 10% dose impact from the Change Healthcare cyberattack. There was a 28% increase in total doses written and a 15% rise in doses filled compared to Q4 2023. The company ended Q1 with $58.4 million in cash and equivalents. Key developments include enrolling the first patient in a PK study for an 80mg/1mL auto-injector and submitting a sNDA to expand FUROSCIX's indication to NYHA Class IV heart failure patients, with a PDUFA date set for August 2024. However, scPharmaceuticals reported a net loss of $14.1 million for the quarter, with increased R&D and SG&A expenses.
- Generated $6.1 million in net FUROSCIX® revenue in Q1 2024.
- 28% increase in total FUROSCIX doses written compared to Q4 2023.
- 15% increase in FUROSCIX doses filled compared to Q4 2023.
- 6.1 doses per prescription, up from 5.9 in Q4 2023.
- 2,184 unique prescribers of FUROSCIX since launch, 29% increase from Q4 2023.
- Completed 2,938 FUROSCIX in-services since launch, up from 2,331 in Q4 2023.
- Enrolled first patient in pivotal PK study for 80mg/1mL auto-injector.
- Submitted sNDA to expand FUROSCIX indication to NYHA Class IV heart failure patients.
- Ended Q1 with $58.4 million in cash and cash equivalents.
- Net loss of $14.1 million for Q1 2024, compared to $11.2 million for Q1 2023.
- Gross-to-net discount increased to 19%, with expectations to rise further.
- R&D expenses increased to $2.7 million from $2.1 million in Q1 2023.
- SG&A expenses rose to $17.4 million from $10.9 million in Q1 2023.
- Impact of Change Healthcare cyberattack resulted in a 10% reduction in doses filled.
Insights
scPharmaceuticals Inc. reported
The enrollment of the first patient in the pivotal pharmacokinetic (PK) study for the 80mg/1mL auto-injector and the submission of a supplemental New Drug Application (sNDA) to the FDA are significant milestones for scPharmaceuticals. These developments could potentially expand the usage of FUROSCIX to include patients with New York Heart Association (NYHA) Class IV heart failure and chronic kidney disease, broadening the market for their product. The PK study and subsequent sNDA submission by the end of 2024 indicate a proactive approach in product development, which could lead to increased adoption by healthcare providers. Investors should note the potential long-term growth from these initiatives, balancing it against the current financial performance.
Generated 1Q 2024 net FUROSCIX® revenue of
Ended 1Q 2024 with cash and cash equivalents of
Company to host investor conference call and webcast today, Tuesday, May 14, at 4:30pm ET
BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
Business Update
- For the first quarter ended March 31, 2024, scPharmaceuticals reports:
- Net FUROSCIX revenue of
$6.1 million , despite an estimated10% negative impact to doses filled during the first quarter resulting from the Change Healthcare cyberattack as well as seasonality resulting from patient copays resetting - 17,376 total FUROSCIX doses written, up
28% sequentially as compared to 13,542 in the fourth quarter of 2023- 8,074 FUROSCIX doses filled, up
15% sequentially from 7,016 in the fourth quarter of 2023
- 8,074 FUROSCIX doses filled, up
- 6.1 doses per prescription, up from 5.9 in the fourth quarter of 2023
- 2,184 unique prescribers of FUROSCIX from launch through end of the first quarter of 2024, up
29% from 1,696 from launch through the end of the fourth quarter of 2023 - 2,938 FUROSCIX in-services completed from launch through end of the first quarter of 2024, up from 2,331 from launch through the end of the fourth quarter of 2023
- Gross-to-net discount of
19% during the first quarter of 2024 - Inventory levels at specialty pharmacy partners remained generally consistent with December 31, 2023 levels
- Net FUROSCIX revenue of
- Continued to see sales of FUROSCIX to integrated Delivery Networks (IDNs)
- Completed transition to new patient services provider/Specialty Pharmacy network
- Enrolled first patient in pivotal pharmacokinetic (PK) study to support development of an 80mg/1mL auto-injector. If successful, scPharmaceuticals plans to submit a supplemental New Drug Application (sNDA) to the FDA by the end of 2024
- Announced that the Company’s sNDA submission to the FDA seeking to expand the FUROSCIX indication to include New York Heart Association Class IV heart failure patients is currently under review by the FDA. A PDUFA date has been scheduled for August 2024
- Ended the first quarter of 2024 with cash and cash equivalents of
$58.4 million
“During the first quarter, we sustained sales momentum. We generated FUROSCIX net revenue of
“Our reported gross-to-net discount of
“Also, during the first quarter, we continued to advance the life cycle and long-term growth initiatives for FUROSCIX that were announced previously. These include the potential expansion of the FUROSCIX indication to include NYHA Class IV heart failure patients, which is currently under review by the FDA, and an expansion of the label to include chronic kidney disease, for which we submitted a sNDA earlier this month. We also recently initiated a PK study to support the development of a low volume auto-injector for FUROSCIX that would complement the current on-body infusor and provide prescribers with treatment flexibility, and we plan to file a sNDA by the end of this year, if successful.”
“We believe that our current commercial trajectory, together with these long-term growth initiatives, form a solid foundation from which we can drive FUROSCIX sales growth in the years ahead,” Mr. Tucker concluded.
First Quarter 2024 Financial Results
Product revenues were
Research and development expenses were
Selling, general and administrative expenses were
scPharmaceuticals reported a net loss of
As of March 31, 2024, scPharmaceuticals’ total shares outstanding was 36,054,409.
Conference call and webcast information
scPharmaceuticals’ management will host a conference call and webcast to review the Company’s first quarter 2024 results today, Tuesday, May 14th, at 4:30 p.m. ET. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13745813.
To access the Call me™ feature, which avoids having to wait for an operator, click here.
A link to the live webcast can be found here.
Following the live webcast, a replay of the event will be archived on scPharmaceuticals’ website for one year.
FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous use
FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of FUROSCIX.
IMPORTANT SAFETY INFORMATION
FUROSCIX is contraindicated in patients with anuria, patients with a history of hypersensitivity to furosemide or medical adhesives and in patients with hepatic cirrhosis or ascites.
Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital.
Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.
Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.
The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
For more details, please read the full Prescribing Information at FUROSCIX.com/prescribing-information.pdf and Instructions for Use at FUROSCIX.com/instructions-for-use.pdf.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our future results of operations and financial position, including reported gross-to-net discount, the potential market impact and benefits of FUROSCIX and the success of the commercialization of FUROSCIX, the trial initiation, anticipated results, clinical design, potential regulatory submissions, approvals and timing thereof of the PK study, the potential expansion of the FUROSCIX indication to include NYHA Class IV heart failure patients and the timing thereof, the potential for continued sales of FUROSCIX to IDNs, the potential expansion of the FUROSCIX indication to include treatment of edema in patients with chronic kidney disease, and the potential impact of the Change Healthcare attack. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates, risks related to the receipt of regulatory approval for our product candidates, risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved , risks related to our history of operating losses, and the risk that global economic factors and uncertainties will impact the Company’s operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com
| scPharmaceuticals Inc. | ||||||||
| Unaudited Consolidated Statements of Operations | ||||||||
| (in thousands, except share and per share data) | ||||||||
| THREE MONTHS ENDED MARCH 31, | ||||||||
| 2023 | 2024 | |||||||
| Product revenues, net | $ | 2,063 | $ | 6,102 | ||||
| Operating expenses: | ||||||||
| Cost of product revenues | 605 | 1,785 | ||||||
| Research and development | 2,116 | 2,726 | ||||||
| Selling, general and administrative | 10,896 | 17,447 | ||||||
| Total operating expenses | 13,617 | 21,958 | ||||||
| Loss from operations | (11,554 | ) | (15,856 | ) | ||||
| Other income | 990 | 2,972 | ||||||
| Interest income | 1,315 | 877 | ||||||
| Interest expense | (1,961 | ) | (2,101 | ) | ||||
| Net loss | $ | (11,210 | ) | $ | (14,108 | ) | ||
| Net loss per share, basic and diluted | $ | (0.30 | ) | $ | (0.36 | ) | ||
| Weighted—average common shares outstanding, basic and diluted | 37,800,960 | 38,952,131 | ||||||
| scPharmaceuticals Inc. | |||||||||
| Unaudited Consolidated Balance Sheet Data | |||||||||
| (in thousands) | DECEMBER 31, | MARCH 31, | |||||||
| 2023 | 2024 | ||||||||
| Cash, cash equivalents and investments | $ | 76,013 | $ | 58,447 | |||||
| Working capital | 79,804 | 64,207 | |||||||
| Total assets | 94,479 | 78,454 | |||||||
| Term loan | 38,811 | 39,385 | |||||||
| Accumulated deficit | (281,346 | ) | (295,454 | ) | |||||
| Total stockholders’ equity | 37,218 | 24,566 | |||||||
FAQ
What were scPharmaceuticals' Q1 2024 net revenues for FUROSCIX?
How did the Change Healthcare cyberattack affect SCPH in Q1 2024?
How did SCPH's FUROSCIX doses change in Q1 2024 compared to Q4 2023?
What was SCPH's cash position at the end of Q1 2024?
What were the financial losses reported by SCPH for Q1 2024?
What is the status of SCPH's sNDA for FUROSCIX expansion to NYHA Class IV heart failure patients?
